A study of the Incidence of Cytomegalovirus infection and Preemptive Therapy in Kidney Transplant Recipients

Authors

  • Zana Sidiq M Saleem Department of Internal Medicine, College of Medicine, University of Duhok, Duhok, Iraq.
  • Kais H Abd Duhok Renal Dialysis and organ transplant Center, Duhok, Kurdistan Region, Iraq.
  • Nashwan M.R. Ibrahim Department of Surgery, College of Medicine, University of Duhok, Duhok, Iraq.
  • Nawfal R Hussein Department of Medicine, College of Medicine, University of Zakho, Zakho, Kurdistan region, Iraq.
  • Hasanain MA Al-Khammas Basrah Center for Kidney Disease and Renal Transplant center, Ministry of Health, Basrah, Iraq.

DOI:

https://doi.org/10.22317/jcms.v8i1.1125

Keywords:

CMV; Preemptive; Iraq; kidney; transplant

Abstract

Objectives: This project aimed to determine the incidence of CVM infection and evaluate the outcome of preemptive treatment.

Methods: This prospective, two centers cohort study included recipients who underwent renal transplant between May 2019-May 2020. The incidence of CMV infection and graft outcomes were studied. All managed with preemptive therapy.

Results: In this study, 134 renal transplant recipients were recruited. Among them, 30/134 (22.4%) patients tested positive for CMV-RTPCR. We studied the impact of age on the CMV-positivity and we found that the age of the doner was associated with CMV-positivity (P= 0.025; OR= 0.923; CI= 0.8584-0.9943). Smoking and gender showed no association with CMV-positivity.

Conclusions: our data suggest that the course of CMV infection is benign with a high success rate of preemptive treatment. Further evaluation for the universal prophylactic plan is needed.

References

Naqid IA, Yousif SH, Hussein NR. Serological Study of IgG and IgM Antibodies to Cytomegalovirus and Toxoplasma Infections in Pregnant Women in Zakho City, Kurdistan Region, Iraq. Women’s Health Bulletin. 2019;6(4):8-12.

Hussein N, Balatay AA. The Seroprevalence of Toxoplasma, Cytomegalovirus and Rubella Infections in Women with Abortion in Kurdistan Region of Iraq: A Brief Report. International Journal of Infection. 2019;6(1):e86734.

Nangle S, Mitra S, Roskos S, Havlichek D. Cytomegalovirus infection in immunocompetent adults: Is observation still the best strategy? IDCases. 2018;14:e00442-e.

Hasegawa J, Hatakeyama S, Wakai S, Omoto K, Okumi M, Tanabe K, et al. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients. Int J Infect Dis. 2017;65:50-6.

Mozaffar M, Shahidi S, Mansourian M, Badri S. Optimal Use of Ganciclovir and Valganciclovir in Transplanted Patients: How Does It Relate to the Outcome? J Transplant. 2018;2018:8414385-.

Requião-Moura LR, deMatos ACC, Pacheco-Silva A. Cytomegalovirus infection in renal transplantation: clinical aspects, management and the perspectives. Einstein (Sao Paulo). 2015;13(1):142-8.

Hussein N, Saleem Z. Successful treatment of hepatitis C virus genotype 4 in renal transplant recipients with direct‐acting antiviral agents. American Journal of Transplantation. 2016;16(7):2237-8.

Hussein N, Saleem Z, Balatay A, Abd K, Daniel S, Taha A, et al., editors. Seroprevalence of Helicobacter pylori infection in renal transplant recipient attending Duhok kidney disease center. Transplantation proceedings; 2016: Elsevier.

Hussein NR, Saleem ZS, Ibrahim NM, Assafi MS, Daniel S. The Prevalence of HBV Infection in Renal Transplant Recipients and the Impact of Infection on Graft Survival. Acta Medica Iranica. 2019;57(6):381-4.

Hussein NR, Saleem ZSM. Successful Treatment of Acute Hepatitis C Virus (HCV) Infection with Interferon-Free Regimen in a Renal Transplant Patient: The First Case Report. International Journal of Infection. 2017;4(4).

Nebbia G, Mattes FM, Smith C, Hainsworth E, Kopycinski J, Burroughs A, et al. Polyfunctional cytomegalovirus-specific CD4+ and pp65 CD8+ T cells protect against high-level replication after liver transplantation. Am J Transplant. 2008;8(12):2590-9.

Giménez E, Blanco-Lobo P, Muñoz-Cobo B, Solano C, Amat P, Pérez-Romero P, et al. Role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infection in an allogeneic stem-cell transplantation setting. J Gen Virol. 2015;96(9):2822-31.

Gerna G, Lilleri D. Human cytomegalovirus (HCMV) infection/re-infection: development of a protective HCMV vaccine. New Microbiol. 2019;42(1):1-20.

Tarragó D, Quereda C, Tenorio A. Different cytomegalovirus glycoprotein B genotype distribution in serum and cerebrospinal fluid specimens determined by a novel multiplex nested PCR. J Clin Microbiol. 2003;41(7):2872-7.

Torok-Storb B, Boeckh M, Hoy C, Leisenring W, Myerson D, Gooley T. Association of specific cytomegalovirus genotypes with death from myelosuppression after marrow transplantation. Blood. 1997;90(5):2097-102.

Babazadeh A, Javanian M, Oliaei F, Akbari R, Akbarzadepasha A, Bijani A, et al. Incidence and risk factors for cytomegalovirus in kidney transplant patients in Babol, northern Iran. Caspian J Intern Med. 2017;8(1):23-9.

Downloads

Published

2022-02-26

How to Cite

M Saleem, Z. S., H Abd, K. ., Ibrahim, N. M. ., Hussein, N. R. ., & Al-Khammas, H. M. (2022). A study of the Incidence of Cytomegalovirus infection and Preemptive Therapy in Kidney Transplant Recipients. Journal of Contemporary Medical Sciences, 8(1), 44–46. https://doi.org/10.22317/jcms.v8i1.1125

Issue

Vol. 8 No. 1 (2022): January-February 2022

Section

Articles

License

Copyright (c) 2022 Journal of Contemporary Medical Sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.